BACKGROUND: The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors. OBJECTIVE: We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients. STUDY DESIGN: NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples. RESULTS: No S282T variant was detected in the 16 analyzed samples. CONCLUSION: This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds.
BACKGROUND: The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors. OBJECTIVE: We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients. STUDY DESIGN: NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples. RESULTS: No S282T variant was detected in the 16 analyzed samples. CONCLUSION: This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds.
Authors: Hala Rady Ahmed; Nancy G F M Waly; Rehab Mahmoud Abd El-Baky; Ramadan Yahia; Helal F Hetta; Amr M Elsayed; Reham Ali Ibrahem Journal: PLoS One Date: 2021-04-15 Impact factor: 3.240
Authors: V Stalin Raj; Gadissa Bedada Hundie; Anita C Schürch; Saskia L Smits; Suzan D Pas; Sophie Le Pogam; Harry L A Janssen; Rob J de Knegt; Albert D M E Osterhaus; Isabel Najera; Charles A Boucher; Bart L Haagmans Journal: Sci Rep Date: 2017-07-05 Impact factor: 4.379